It is well known fact that the strengths of drug interactions with grapefruit juice (GFJ) diŠer greatly depending on the 1,4-dihydropyridine calcium channel antagonist (DHP) used. However, there are no available data on the relationship between interactions with GFJ and its physicochemical attributes. Therefore we endeavored to study the correlation between calculated logP values, indicating lipophilicity, from chemical structures of DHPs as well as water diŠusion, molecular volume, molecular polarization, molecular density, refractive index, topologic polar surface area, and calculated molar refractivity. Thirteen forms of DHP, amlodipine, azelnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, and pranidipine were analyzed due to clinical trials performed with GFJ and these agents. The pharmacokinetic interaction strengths were deˆned in common logarithmic values of increasing ratios of area under the plasma concentration-time curve (AUC) with GFJ intake compared with controls. Physicochemical properties including three categories of predicted logP values were calculated from the structures of DHPs and their estimated relationship with the interactions. As a result, the logP values indicated signiˆcant positive correlations with the interaction strengths. Thisˆnding suggests that lipophilicity is an important factor in the strengths of pharmacokinetic interactions of DHPs with GFJ intake.
INTRODUCTION

1,4-Dihydropyridine calcium channel antagonists
(DHPs) are one of the major categories of drugs with reported pharmacokinetic interactions, such as the increasing drug levels in plasma with concomitant intake of GFJ. 1 11) This group of compounds has a 1,4-dihydropyridine group in a common chemical structure.
CYP3A 12) is expressed in human intestine 13) and liver 14) which has oxidized the structure of the pyridine ring 15) and, as a result, the calcium channelblocking capacities of these drugs disappear. GFJ inhibits the activity of CYP3A expressed in the intestine, 16) since it is theˆrst contact enzyme for the oxidation of orally administered DHPs. Intestinal CYP3A decreases through mechanism-based inhibition 17) of GFJ components, furanocoumarin derivatives such as bergamottin, 6′ ,7′ -dihydroxybergamottin, and furanocoumarin dimers such as paradisin A, paradisin B, and paradisin C. 18 22) As a result, part of the intestinal barrier capacity for xenobiotics decreases for at least 3 days. 23) Accordingly, the bioavailability of parent compounds with the 1,4-dihydropyridine ring found in many types of DHP and the level in systemic circulation increase after concomitant intake of GFJ.
Generally, patients who a administered DHPs are instructed in clinical practice to avoid GFJ consumption because these interactions induce side eŠects. 3) On the other hand, the strength of the interaction is dependent upon the type of drug used. 1 11) For example, the ratio of the area under the plasma concentration-time curve (AUC) of orally administered DHPs between patients drinking GFJ and those who do not was found to vary greatly and ranged from × 1.1 in the case of amlodipine 1) to ×3.3 in the case of azelnidipine. 9) The structural and physicochemical properties of currently used DHPs vary signiˆcantly, and the extent of interactions is considered attributable to the physicochemical characteristics. However, little is known about the correlation between the structures and the clinical interaction strengths (CISs). Therefore analysis was performed using the predictive properties calculated from the chemical structures and the reported pharmacokinetic interactions with GFJ consumption. 
METHODS
Thirteen DHPs, amlodipine, azelnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, and pranidipine, on which there were conˆrmable reports of pharmacokinetic interactions with GFJ were selected for analysis. CISs were dened as common logarithmic values of the AUC increasing ratio, in which the AUC of each DHP with GFJ consumption was divided by the corresponding control AUC. Theˆrst report with a signiˆcant interaction with GFJ intake for each drug was referred to the AUC value to avoid the variation of CIS in publication bias. Three types of predicted logP values, ALOGPs, 24) ClogP, 25) and XLOGP, 26) and seven other physicochemical properties, water diŠusion, molecular volume, molecular polarization, molecular density, refractive index, topologic polar surface area, and calculated molar refractivity, were calculated from the chemical structures using ChemDraw 10.0 (for CLogP, topologic polar surface area, and calculated molar refractivity, Cambridge Soft Corporation, MA, US), ALOGPS 2.1 27) (for ALOGPs and XLOGP, Virtual Computational Chemistry Laboratory, http://www.vcclab.org), and Sparc On Line Calculator v3.1 28) (for water diŠusion, molecular volume, molecular polarization, molecular density, and refractive index, University of Georgia, GA, US) which were used for analyzing the physicochemical characteristics of DHPs. Linear regression analyses were performed using the least-squares method in which objective variable and explanatory variable were CISs and predicted physicochemical properties, respectively. The signiˆcance level was set at p＜0.05.
RESULTS
Strengths of Interactions between DHPs and GFJ
Conditions in the clinical trials for the 13 DHPs (Fig.  1 ) orally administered with GFJ are shown in Table  1 . Drugs used in the trials simultaneously administered with GFJ. The administration volume of GFJ ranged from 150 to 300 ml. Alternatively, AUC ratios between the GFJ and non-GFJ groups ranged Tables 2 and 3 , respectively. Analyses using the linear least-squares method for relationship between the physicochemical properties and CISs represent each logP value, CLogP, ALOGPs, and XLOGP, but not water diŠusion, molecular volume, molecular polarization, molecular density, refractive index, topologic polar surface area, and calculated molar refractivity, correlated with CIS : CIS＝0.0822ALOGPs-0.0651, r＝0.626; CIS ＝ 0.0569ClogP -0.0276, r ＝ 0.592; CIS ＝ 0.0582XLOGP＋0.0272, r＝0.587 (Fig. 2) .
DISCUSSION
The present study was conducted to estimate the eŠects of the physicochemical properties of DHPs on the strength of interaction with GFJ. DHPs are the major focus of studies of the pharmacokinetic interactions with concomitant intake of GFJ. 1 11,29) These compounds have a 1,4-dihydropyridine ring as a common structure. This partial structure is characterized by substrates of cytochrome P450, which form a pyridine ring as a result of the enzymatic reaction. 15, 30, 31) The aromatic-ring formation reaction is caused by the DHPs losing their calcium antagonistic eŠect.
It has been considered that interactions relating to GFJ were caused by inhibition of aˆrst-pass metabolism of the dihydropyridine site with CYP3A in the intestinal mucosal cells. 32) DHPs used in clinical practice have a variety of chemical structures, suggesting various physicochemical and pharmacokinetic properties. The extent of interaction varies greatly among DHPs (Table 1) . However, there has been little research into the relationship between the variability of the interactions and the physicochemical properties. In the present study,ˆndings from clinical trials were used in calculating CISs, and the conditions of pharmacokinetic investigation in the reports diŠered, resulting in errors among pharmacokinetic data. Nevertheless, the results showed that the relationship between CISs and the predicted logP values for the 13 DHPs indicated signiˆcant correlation, which was expressed as simple linear regression formulae. These results suggest that the lipophilicity of the drugs is an important factor in the interactions. It is considered that the clearance of DHPs inˆrst-pass metabolism is regulated by intestinal and hepatic intrinsic clearance.
Because the target organ of GFJ is the intestine, it has been speculated that DHP with a higher contribution ratio of intestinal clearance in theˆrst pass has stronger interaction with the concomitant consumption of GFJ. Ohnishi et al. reported that the plasma protein-binding ratio correlated with an increasing ratio of AUC for calcium-blocking agents with the consumption of GFJ. 2) This suggested the possibility that drugs that have higher plasma unbound fractions re‰ect a higher percentage of contribution of the intestinal metabolism inˆrst-pass eŠect due to a lower hepatic extraction ratio.
LogP values are a parameter-informed correlation with the plasma protein binding of drugs 33, 34) and, because of this, it is conceivable that the present results support the report showing a correlation between the extent of the interactions and protein-binding ratios. 2) Furthermore, it is known that lipophilicity is one of the parameters contributing to absorption, 35) distribution, 36, 37) metabolism, 38) and excretion 36, 39) in pharmacokinetics. For example, enzymatic a‹nities and kinetic properties in CYP oxidation of various compounds are regulated by the logP values of the substrates. 40) Therefore it is speculated that the lipophilicity of drugs contributes to the pharmacokinetic properties of DHPs oxidizing with intestinal CYP3A. On the other hand, some DHPs showed values that were distant from the linear regression in Fig. 2 . This observation possibly suggests that alternative factors other than CYP3A, such as drug transporters in the intestine, may be involved in the interactions. It has been reported that concomitant intake of GFJ causes an increase in the plasma concentration of P-glycoprotein substrates such as cyclosporine 41) and a decrease in the plasma concentration of organic anion transporting peptide (OATP) substrates such as fexofenadine. 42) ALOGPs were considered to be the most appropriate algorithm to assess the interactions between the three types of predicted logP values examined in this study because they showed the best correlation. ALOGPs were used to predict the extent of GFJ interactions with DHPs, which has not been reported to date. As a result, lercanidipine and niguldipine (ALOGPs: 6.42 and 6.27, respectively) were estimated to be high-risk drugs showing a predictive increase of 300％ in the AUC with GFJ intake. Alternatively, it was suggested that aranidipine and nilvadipine (ALOGPs: 2.71 and 2.97, respectively) which are used in Japanese clinical practice, are relatively safe drugs comparable to nifedipine, with a predicted AUC increase with GFJ of about 150％. The adequacy of these prognostics has yet to be demonstrated in terms of clinical trials, although the structural analyses in this study will be useful to predict the harmfulness of drugs in interactions with GFJ.
